Gene editing, a set of techniques used to alter sections of an organism's DNA, is helping scientists cure diseases previously ...

Gene therapy and gene editing are marvels of modern biotechnology, providing revolutionary techniques for fixing genetic abnormalities. Gene therapy introduces functional genetic material to ...

Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.

As of this writing, Figma (NYSE: FIG) is the most recent stock to be purchased for Cathie Wood's Ark Innovation ETF. Ark purchased shares of the stock for the fund on Feb. 23, marking the third time ...

Intellia TherapeuticsNTLA stock shot higher Tuesday after the Food and Drug Administration said it would allow the company to restart a study of its gene-editing drug in patients with polyneuropathy.

BioMarin Pharmaceuticals Inc. (NASDAQ:BMRN) stands third among the most promising stocks. TheFly reported on December 19 that BMRN announced it will acquire Amicus Therapeutics in an all‑cash ...

O3, Lauren Goodwin, New York Life Investments, appeared on CNBC’s ‘Closing Bell’ to talk about the state of equity markets ...

Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Jan. 2, 2026 /PRNewswire/ -- Equity Insider News Commentary – The gene therapy market is surging toward $36.55 billion by 2032, powered by ...

On the final trading day of 2025, Cathie Wood put an eye-brow raising $1.33 million to work in Intellia Therapeutics (NTLA), scooping up 145,153 shares in the gene-editing play. For the most part, it ...

DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic ...

The MarketWatch News Department was not involved in the creation of this content. Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Jan. 2, 2026 /CNW/ -- Equity Insider News Commentary -- The ...